JNJ's Q2 beat provides relief, but key risks remain unresolved

What happened

Johnson & Johnson reported strong Q2 2026 results, with revenue up 6.6% year over year to $25.3 billion, driven by oncology drug DARZALEX and immunology drug TREMFYA, leading management to raise full-year guidance. The company also announced label expansions: CAPLYTA now approved for schizophrenia relapse prevention, and IMAAVY positioned as a potential first-mover in warm autoimmune hemolytic anemia (wAIHA). However, these results come against a backdrop of STELARA biosimilar erosion, which caused a 59.7% year-over-year sales decline in Q1 2026, and the CVS Caremark formulary switch away from STELARA effective July 1, 2026, whose impact will only be visible in Q3. Talc litigation remains an open-ended risk, with management unable to estimate losses beyond the current $3.4 billion reserve, and recent court developments could increase plaintiff leverage. While the Q2 performance and pipeline catalysts are positive, they do not yet confirm that the company has fully absorbed the payer-driven step-down in immunology or that talc liabilities are contained.

Implication

The Q2 beat and raised guidance suggest that JNJ's growth drivers are offsetting STELARA erosion better than feared, but the CVS formulary switch on July 1, 2026, means Q3 will be a more critical test. Talc litigation remains a wild card, with potential for large incremental liabilities beyond the current reserve. The label expansions add optionality but are unlikely to contribute materially to near-term revenue. Given the stock's recent run-up (price near $228-240) and the unresolved risks, the WAIT rating from the master report remains appropriate. Investors should look for better entry points below $220 or wait for evidence of sustainable growth post-STELARA and any positive talc developments before adding positions.

Thesis delta

The positive Q2 results and raised guidance modestly increase confidence that JNJ's growth drivers can compensate for STELARA erosion, shifting probability weight toward the base and bull cases. However, the key near-term risks—the post-CVS STELARA trajectory and talc litigation—remain unresolved, so the thesis does not warrant an upgrade to BUY. The rating remains WAIT, but with a slightly narrower discount to fair value as execution improves.